1. Introduction {#s0005}
===============

Migraine is a primary form of headache characterized by recurrent episodes of debilitating headache, sometimes preceded by transient neurological symptoms named aura. Its pathophysiology recognizes a unique mixture of bio-psycho-social aspects, which may all trigger the attack in susceptible individuals, unveiling a biological predisposition of a dysexcitable brain to convert non-painful stimulation into headache pain. This ultimately leads to impressive disability, significant productivity loss, huge economic burden and healthcare resource use.

In the last two decades, an unprecedented number of studies have contributed to substantial advances in abortive and preventive therapy, opening new and promising scenarios in the field of precision medicine. Nonetheless, migraine remains a major clinical challenge, as it is often under-diagnosed [@b0005]. Current validated diagnostic criteria, in fact, distinguish migraine according to the attack frequency (episodic or chronic) or to the presence/absence of aura [@b0010], but do not disentangle the different endophenotypes of this highly heterogeneous headache disorder [@b0015]. Furthermore, preventative migraine medications are often underutilized, leaving patients at-risk of medication overuse (MO), disease progression, higher disability and increased healthcare costs [@b0020]. MO affects approximately 15% of migraine patients [@b0025] and is the most relevant risk factor for migraine chronicization [@b0030] as well as the development of a secondary headache disorder known as medication-overuse headache (MOH) [@b0010], [@b0035], [@b0040]. Daily or weekly analgesic use, in fact, disproportionately increases the risk for chronic migraine (RR = 13.3, 95% CI: 9.3--19.1) as documented by a large prospective population survey [@b0045]. When considering a specialized headache center setting, the odds for developing chronic migraine 1 year later in patients with episodic migraine with MO is 19.4 times (95% CI: 8.7--43.2) higher than in those without [@b0050]. The risk of chronic migraine progression is further incremented when overusing involves acute medications containing barbiturates (OR = 2.1; 95% CI: 1.3--3.1) or opioids (OR = 1.2; 95% CI: 1.4--2.2), compared with acetaminophen, as hinted by the American Migraine Prevalence and Prevention (AMPP) study [@b0055]. This is also true in adolescents, in whom medication overuse is a predictor of migraine chronic evolution (HR = 2.5; 95% CI: 1.1--5.5) [@b0060]. Once established, MOH is the epitome of hard to treat neurological disorders due to its disappointing response to treatment and frequent relapse.

Thus, the possibility of predicting MO, or estimating the efficacy of a given therapy, is a compelling challenge in the clinical management of migraine to set out prevention programs for patients prone to frequent headache.

Artificial intelligence (AI) with machine learning (ML) has shown great potential in building automatic predictors in the field of migraine [@b0065], [@b0070], [@b0075], [@b0080], [@b0085], [@b0090], [@b0095], [@b0100], [@b0105], [@b0110] but detectors for MO are still in their infancy [@b0100]. In fact, many AI models have been applied for nearly 10 years to implement medical decision support systems for the diagnosis of migraine [@b0065], [@b0070], [@b0075], [@b0080], [@b0085], [@b0090], [@b0095], [@b0100] and for predicting migraine treatment outcomes [@b0105], [@b0110]. For example, artificial neural networks (ANNs), artificial immune systems (AIS) and support vector machines (SVM) have shown encouraging results. Some systems were built on clinical dataset derived from patients' medical records [@b0065], [@b0070], [@b0075], [@b0080], [@b0085], while others analyzed data from resting-state functional magnetic resonance neuroimaging (rs-fMRI) [@b0090], [@b0095], [@b0100]. All these studies demonstrated that intelligent systems represent a promising approach for migraine classification, holding potential to revolutionize conventional models of diagnostic deliverance in a contest of personalized medicine. However, To the best of our knowledge, there is only one study studying the potential of AI in predicting MO [@b0100]. In their study, Garcia-Chimeno et al. reported the possibility to distinguish between patients with episodic or chronic migraine with MO via feature selection techniques and machine learning [@b0100]. Using SVM, Boosting and Naive Bayes they obtained an overall classification with over 93% accuracy. However, the study had a big major limitation: due to the small number of participants (n = 18 for chronic migraine with MO), the testing was undertaken in the same dataset used for training and no holdout test set was used [@b0100]. Moreover, the specific aim was not to predict MO risk, but to correctly classify between different migraine phenotypes [@b0100]. Thus, there is still an unmet need to develop classifications models that embody the newest AI technologies and can be used to predict MO in individual migraine patients for a personalized patient care.

In this study, we present our approach RO-MO to use machine learning along with Random Optimization (RO) for predicting Medication Overuse (MO) in migraine patients. Our approach in this study solves the problems of previous studies [@b0100] as testing has been carried out in a held-out set and RO-MO outperforms SVM as used in [@b0100]. RO-MO derives from our previous studies. In a perspective of predictive medicine and tailored therapy, we have recently demonstrated that an approach based on AI methodologies holds the potential to devise decision support systems (DSSs) that can be adapted to different medical problems [@b0115], [@b0120], [@b0125], [@b0130]. Our model based on Multiple Kernel Learning (MKL) [@b0135], combines SVM [@b0140] algorithm and Random Optimization (RO) [@b0145], offering the possibility to inspect the learned model and providing an estimate of the relative weight of routinely collected demographic, clinical and biochemical data in predictions. This model -- originally developed for cancer-associated thrombosis risk assessment [@b0115], [@b0120], [@b0125] and then adapted to estimate the risk of disease progression of breast cancer patients [@b0130] -- seeks not only decision, but also interpretability of the model itself, which represents the novel aspect of our research. Based on previous observations, we hypothesized that our previous approach could be of assistance in predicting the risk of MO in migraine patients. To achieve this objective, a proof-of-concept study was specifically designed produce MO risk predictors (RO-MO) using real world data from a large, well clinical characterized migraine outpatient population, detailing lifestyle, behavioral and socio-demographic factors and clinical phenotype. The performance of RO-MO was also compared with that of baseline SVM to assess the significance of optimizing the relative importance of groups of clinical attributes in the selection of MO risk predictors.

2. Patients and methods {#s0010}
=======================

2.1. Patient's dataset {#s0015}
----------------------

Starting from January 2008, the Headache and Pain Unit of the Department of Neurological, Motor and Sensorial Sciences and the InterInstitutional Multidisciplinary Biobank (BioBIM) of the IRCCS San Raffaele Pisana, Rome, Italy, are jointly involved in the recruitment of outpatients affected by headache, who are prospectively followed under the appropriate Institutional ethics approval and in accordance with the principles embodied in the Declaration of Helsinki [@b0150]. All patients undergo a careful physical and neurological examination performed by trained neurologists (PB, GE, LF) and are screened with face-to-face interviews using a semi-structured questionnaire formulated to collect thorough data on lifestyle, behavioral and socio-demographic factors (age, sex, civil status, occupation, body mass index, arterial blood pressure, sport activity, use of coffee, alcohol, smoking, sleep disturbances, menopause, contraceptive use), comorbidities and concomitant medications and clinical features of migraine (disease duration, family history of migraine, presence, frequency, duration of attacks, location, accompanying symptoms, unilateral cranial autonomic symptoms, triggers and alleviating factors, prodromes, postdromes, allodynia, presence and duration of medication overuse, current acute or preventive medications, patient's satisfaction with triptans) [@b0155]. All patients provide written informed consent, previously approved by the local Institutional Review Board, to donate a blood sample to be used in the analysis of possible determinants of migraine outcome or response to treatment.

Blood samples are withdrawn in fasting conditions and processed using standard operating procedures, ICT tools and dedicated software to track the entire sample life, including elapsed time between blood withdrawal and storage [@b0150]. Routine biochemical analyses are performed on fresh blood samples at time of enrolment. Thereafter, blood samples are processed, aliquoted, coded, and stored at −80 °C for subsequent batch analyses. Storage conditions are carefully monitored, and all aliquots are limited to one freeze--thaw cycle to ensure the best sample quality. For the present study, 777 consecutive migraine patients were analyzed.

2.2. Experimental settings and statistical analysis {#s0020}
---------------------------------------------------

Our MO risk predictor is based on multiple kernel learning over support vector machines and Random Optimization (RO-MO). We built RO-MO in KELP [@b0160] as previously reported [@b0115]. RO-MO was used to produce prognostic discriminators (referred as RO-MO-x) yielding the best classification performance over a training (3-fold cross validation) and test set. Twenty different learning sessions with 20 different RO initializations were performed. The dataset, consisting of 777 patients, was randomly divided into a training and a test set. The training set consisted of 543 migraine patients (70% of the dataset); the remaining 234 patients were allocated to the test set (30% of the cases).

Baseline SVM was run on weka platform and its performance was evaluated in comparison with RO-MO classifiers.

Demographic, clinical and biochemical characteristics of the training and test sets are summarized in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}.Table 1Clinical features of migraine patients in the training and test set.TrainingTestP value**Sex**, N (%)0.513Male96 (17.7)46 (19.7)Female447 (82.3)188 (80.3)**Menopausal status**0.235Pre327 (73.2)146 (77.7)Post120 (26.8)42 (22.3)Age at menarche12.2 ± 1.212.2 ± 1.40.875**Age** (Years), Mean ± SD (range)41.5 ± 13.2 (13--78)39.5 ± 12.5 (17--71)0.052**BMI**, Mean ± SD (range)23.9 ± 3.8 (17.0--46.8)23.7 ± 3.6 (15.0--36.5)0.623**Age of onset** (Years), Mean ± SD (range)19.9 ± 11.0 (3--73)19.9 ± 10.7 (4--62)0.970**Length of chronicization** (Years), Median (IQR)2 (1--4)2 (1--5)0.768**Type of migraine**, N (%)0.092Chronic139 (25.6)48 (20.5)Episodic without aura287 (52.9)114 (48.8) Menstrual migraine, N (%)\*181 (40.5)92 (39.3)Episodic with aura85 (15.6)54 (23.1)**Cluster headache**11 (2.0)9 (3.8)0.811**Tension-type headache**21 (3.9)9 (3.8)0.990**Familiarity**, N (%)383 (70.8)168 (72.4)0.648**Frequency** (days/months), Median (IQR)7 (3--15)5 (2--10)0.002**Pain Localization**, N (%)0.377Unilateral357 (65.8)146 (62.4)Unilateral or bilateral4 (0.7)2 (0.8)Bilateral182 (33.5)86 (36.8)**Unilateral cranial autonomic symptoms**, N (%)242 (44.6)103 (44.0)0.887**Dopaminergic symptoms**, N (%)173 (31.9)63 (26.9)0.509**Comorbidities**, N (%)neuropsychiatric167 (30.8)65 (27.8)0.397cardiovascular61 (11.3)22 (9.4)0.439endocrine-metabolic83 (15.4)30 (12.8)0.356**Treatment**, N (%)Type of medication0.009Triptans140 (25.8)71 (30.3)NSAID165 (30.4)74 (31.6)Triptans + NSAID178 (32.8)51 (21.9)Other60 (11.1)38 (16.2)Response to triptans280 (88.0)104 (85.3)0.523Use of prophylaxis304 (56.0)112 (47.9)0.087**Medication overuse**Overusing patients, N (%)127 (23.4)35 (15.0)0.010Abused Drug, N (%)Triptans38 (29.9)9 (25.7)0.437NSAIDs ± combination medications19 (15.0)7 (20.0)Combination medications64 (50.4)15 (42.9)Others8 (6.3)2 (5.7)Quantity of abused drug (tablets/month)34 ± 2933 ± 260.724Overuse duration (Years), Median (IQR)2 (1--4)2 (1--4)0.439[^3][^4]Table 2Biochemical features of migraine patients in the training and test set.TrainingTestP value**Blood cell counts**Red blood cells4.5 ± 0.54.4 ± 0.420.161Haematocrit39.4 ± 3.539.4 ± 3.40.811Hemoglobin13.3 ± 1.313.4 ± 1.20.502White blood cells6.6 ± 1.76.5 ± 1.60.581Neutrophils3.9 ± 1.43.8 ± 1.20.487Lymphocytes2.1 ± 0.62.6 ± 0.60.947Monocytes0.5 ± 0.10.5 ± 0.20.409Platelets230.2 ± 52.1231.7 ± 51.40.818Mean Platelet Volume9.0 ± 1.08.9 ± 1.10.218**Coagulative asset**International Normalized Ratio1.0 ± 0.11.0 ± 0. 10.984Prothrombin Time103.3 ± 13.2104.1 ± 16.30.656aPTT27.9 ± 2.930.5 ± 30.50.228Fibrinogen282.1 ± 54.5279.7 ± 47.60.757**Glucose metabolic asset**Fasting blood glucose (mg/dl), Mean ± SD82.5 ± 11.584.2 ± 10.00.201Fasting insulin (µIU/ml), Mean ± SD9.6 ± 9.210.0 ± 9.80.677HbA~1c~ (%), Mean ± SD5.5 ± 0.35.5 ± 0.40.595**Blood lipids**Total cholesterol (mg/dl), Mean ± SD202.3 ± 35.7195.8 ± 35.30.134HDL-cholesterol (mg/dl), Mean ± SD56.7 ± 14.056.9 ± 12.90.864LDL-cholesterol (mg/dl), Mean ± SD125.2 ± 31.4120.3 ± 30.70.192Triglycerides (mg/dl), Mean ± SD102.2 ± 57.293.3 ± 56.50.196**Blood lipids**Creatinine (mg/dl), Mean ± SD0.80 ± 0.130.78 ± 0.140.414Blood urea nitrogen (mg/dl), Median (IQR)31.5 ± 9.731.4 ± 9.30.897Alanine transaminase17.6 ± 9.218.5 ± 10.60.464Aspartate transaminase18.1 ± 4.618.0 ± 4.90.809Gamma-glutamyl transferase20.0 ± 22.018.2 ± 14.30.442Total bilirubin0.53 ± 0.300.59 ± 0.390.139***DBH 19-bp I/D polymorphism\****0.141II130 (46.3)45 (42.1)ID60 (21.4)33 (30.8)DD91 (32.4)29 (27.1)[^5]

Numerical attributes were analyzed as continuous values. Missing clinical attribute values were treated according to Predictive Value Imputation (PVI) method by replacing missing values with the average of the attribute observed in the training set [@b0165]. Group clustering was performed according to the clinical significance of the attributes included in the patient dataset. These included: demographic characteristics (group 1), migraine clinical features (group 2), treatment details (group 3), presence of co-morbidities (group 4), biochemical variables (group 6) and lifestyle information (group 7). Dopamine-beta-hydroxylase (DBH) 19-bp I/D polymorphism (rs72393728/rs141116007) was individually considered given its proposed association with MO [@b0170]. A detailed list of all the features that have been applied to construct the predictor is reported in [Fig. 1](#f0005){ref-type="fig"}. RO was used to devise their relative weights in final prediction. In RO, relative weights are initialized with random number and estimated by maximizing performance in the 3-fold cross validation. These weights can be used to interpret the importance of the groups of features within the model. Thus, the final DSS is interpretable.Fig. 1Features included in the model.

Receiver operating characteristic (ROC) curve, Bayesian analysis and logistic regression were performed by MedCalc Statistical Software version 13.1.2 (MedCalc Software bvba, Ostend, Belgium) to estimate the probability of medication overuse. All tests were two-tailed and only *p*-values lower than 0.05 were regarded as statistically significant.

3. Results {#s0025}
==========

Overall, 21% (162 of 777) of the enrolled patients reported the presence of MO which had lasted for at least 2 years ([Table 1](#t0005){ref-type="table"}). No substantial differences were observed for clinical and biomolecular variables between patients included in the training and test sets, with the exception of attack frequency, the use of triptans in combination with NSAID and the percentage of patients with MO, which were all slightly higher in the training compared with the test set.

A set of predictors (named RO-MO-x) was identified using a 3-fold cross validation technique on a training set (n = 543). A test set (n = 234) was used to compute the final performance of risk predictors. As shown in [Table 3](#t0015){ref-type="table"}, RO-MO was capable of improving MO risk prediction compared to baseline SVM as demonstrated by a substantial improvement of the f-measure. Thus, to better characterize the performance of the proposed method, the area under the ROC curve (AUC) and positive and negative likelihood ratios (LRs) were also calculated for all RO-MO models in comparison with baseline SVM. As shown in [Table 3](#t0015){ref-type="table"}, RO-MO-08 was the best performing predictor in the training set with an AUC of 0.79, which was significantly higher than that observed for baseline SVM (p = 0.003) ([Table 3](#t0015){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}) and further increased to 0.81 in the test set ([Table 4](#t0020){ref-type="table"}).Table 3Analytical performance of machine learning with random optimization in the training set.ModelPrecisionRecallF-MeasureAUC (SE)95% CI+LR−LRSVM Baseline0.8620.4410.5830.710 (0.0224)0.669--0.74820.40.57RO-MO-050.8190.6830.7450.657 (0.0242)0.615--0.6971.950.53RO-MO-120.7040.7540.7280.737 (0.0223)0.697--0.7732.770.35RO-MO-140.6850.6900.6880.669 (0.0236)0.628--0.7081.930.47RO-MO-130.6910.6750.6830.610 (0.0248)0.567--0.6511.570.64RO-MO-040.6110.6980.6520.683 (0.0241)0.642--0.7222.910.55RO-MO-190.7530.5320.6230.599 (0.0246)0.557--0.6411.800.73RO-MO-030.4830.7700.5930.717 (0.0232)0.677--0.7542.670.41RO-MO-080.4740.7860.5910.787 (0.0219)0.750--0.8215.260.34RO-MO-060.4660.6980.5590.645 (0.0245)0.603--0.6851.890.57RO-MO-090.4200.7940.5490.656 (0.0236)0.614--0.6961.800.49RO-MO-160.3950.8020.5290.696 (0.0230)0.656--0.7352.180.41RO-MO-110.4350.6430.5190.663 (0.0242)0.622--0.7032.770.60RO-MO-070.3960.7540.5190.644 (0.0237)0.602--0.6841.690.51RO-MO-170.3810.7460.5040.639 (0.0233)0.598--0.6803.280.68RO-MO-180.4050.6430.4970.681 (0.0223)0.640--0.7211.890.39RO-MO-150.4650.5320.4960.666 (0.0230)0.624--0.7051.810.44RO-MO-010.3630.7460.4880.714 (0.0235)0.674--0.7524.710.52RO-MO-020.3390.6510.4460.726 (0.0235)0.687--0.7633.940.47RO-MO-000.2700.7380.3960.511 (0.0235)0.468--0.5541.070.97RO-MO-100.2760.6430.3870.589 (0.0250)0.546--0.6311.570.74Average RO-MO0.5090.6990.5600.6640.705 -- 0.6903.320.54[^6]Fig. 2Comparison between the Receiver Operator Characteristics Curves for RO-MO-08 and SVM baseline predictor in the training set.Table 4Analytical performance of machine learning with random optimization in the test set.ModelPrecisionRecallF-MeasureAUC (SE)95% CI+LR−LRSVM Baseline0.9570.6290.7590.812 (0.0414)0.760--0.86315.00.34RO-MO-000.1610.4290.2340.501 (0.0431)0.436--0.5671.011.00RO-MO-010.3020.4570.3640.625 (0.0439)0.559--0.6872.650.71RO-MO-020.2670.6570.3800.739 (0.0433)0.678--0.7944.170.44RO-MO-030.3820.7430.5050.746 (0.0405)0.685--0.8002.960.34RO-MO-040.3480.6570.4550.688 (0.0447)0.624--0.7472.920.53RO-MO-050.8060.7140.7580.675 (0.0439)0.611--0.7352.140.49RO-MO-060.2840.7140.4070.702 (0.0429)0.639--0.7602.440.44RO-MO-070.2310.6860.3450.683 (0.0412)0.619--0.7421.970.41RO-MO-080.3250.7430.4520.806 (0.0393)0.750--0.8555.690.30RO-MO-090.2450.7140.3650.649 (0.0434)0.585--0.7101.770.51RO-MO-100.2000.4860.2830.606 (0.0459)0.541--0.6691.710.70RO-MO-110.4290.4290.4290.571 (0.0431)0.505--0.6351.710.82RO-MO-120.6760.7140.6940.770 (0.0390)0.711--0.8223.340.30RO-MO-130.4460.7140.5490.597 (0.0444)0.532--0.6611.420.64RO-MO-140.4100.7140.5210.703 (0.0411)0.640--0.7612.210.39RO-MO-150.2320.6290.3380.685 (0.0400)0.621--0.7441.920.38RO-MO-160.2200.6860.3330.687 (0.0431)0.623--0.7462.200.46RO-MO-170.4000.4570.4270.603 (0.0435)0.537--0.6662.240.75RO-MO-180.2390.6290.3460.701 (0.0368)0.638--0.7591.940.30RO-MO-190.4790.6570.5540.632 (0.0455)0.567--0.6941.860.62Average RO-MO0,3820,6310.4520.8120.7283.010.52[^7]

Overall, five RO-MO predictors showed an acceptable predictive performance with AUCs \> 0.70 and significant positive and negative LRs ([Table 3](#t0015){ref-type="table"}), but only RO-MO-02, RO-MO-03, RO-MO-08 and RO-MO-12 confirmed their predictive value in the test set ([Table 4](#t0020){ref-type="table"}, [Fig. 3](#f0015){ref-type="fig"}).Fig. 3Comparison of the predictive performance among the analyzed models.

Of interest, all four predictors were not only clinically plausible -- as demonstrated by the finding that group 2 variables (migraine clinical features) retained the strongest weight in all models ([Table 5](#t0025){ref-type="table"}) -- but they had also a complementary configuration of weights ([Table 5](#t0025){ref-type="table"}, [Fig. 4](#f0020){ref-type="fig"}). In particular, RO-MO-02 was weighted on demographics and co-morbidities, RO-MO-03 on DBH polymorphism, RO-MO-08 on treatment details and lifestyle-related triggers and RO-MO-12 on the biochemical and metabolic asset. These findings are consistent with literature data showing that DBH polymorphism is associated with MO in chronic migraine patients [@b0170] and suggest that patients' metabolic asset, obesity, or lifestyle-related factors might contribute to drug overuse in this clinical setting.Table 5Normalized weights of attribute groups in the training set.ModelGroup 1Group 2Group 3Group 4Group 5Group 6Group 7RO-MO-000.050240.045280.361220.137280.418460.808420.05055RO-MO-010.188940.690450.172020.046810.048580.038360.14286RO-MO-02**0.238911.08083**0.00088**0.24596**0.001380.000110.03468RO-MO-030.05299**1.57451**0.035840.16382**0.33030**0.176910.02008RO-MO-040.000022.226960.075530.146440.125330.012310.04431RO-MO-050.013750.745680.010270.016850.014960.440500.03129RO-MO-060.007221.112370.080350.458950.113000.335770.23231RO-MO-070.005450.388980.016640.145030.344470.092760.19871RO-MO-080.02089**0.927040.49196**0.106730.088130.05844**0.49128**RO-MO-090.182811.115880.082650.145040.407450.007910.09501RO-MO-100.425750.013830.033730.022430.346970.206110.38230RO-MO-110.118970.673531.020920.093010.050420.165030.01637RO-MO-120.00007**1.09627**0.007050.035110.03214**0.46090**0.06996RO-MO-130.006121.454880.030221.454880.027230.030220.15365RO-MO-140.231381.443780.016240.136160.029750.524460.12165RO-MO-150.413761.057720.480820.000060.213780.039780.02857RO-MO-160.000020.674130.046900.158110.547340.033460.65751RO-MO-170.223851.553560.240800.082920.079870.000190.09701RO-MO-180.028001.108220.088510.195430.171630.303260.00743RO-MO-190.421580.448970.031730.063030.021030.250170.01316Fig. 4Normalized weights of groups of clinical attributes for the different models.

As the performance of RO-MO predictors could be further enhanced, we sought to investigate whether the combination of the best binary predictors (RO-MO-02, RO-MO-03, RO-MO-08 and RO-MO-12) into a decision support system (ML-based DSS) could be of advantage over the individual predictors, or baseline SVM. Using this combined model, we were able to classify migraine patients into five categories: definitely not likely to overuse (0, all predictors negative); probably not likely to overuse (1, at least one positive); possibly at risk of drug overuse (2, two of four positive); probably at risk of drug overuse (3, three of four positive); definitely at risk of drug overuse (4, all predictors positive). The discriminatory power of the ML-based DSS was first analyzed in the training set. The results obtained showed an overall improvement of MO risk prediction performance, with an AUC of 0.81 (95% CI: 0.78--0.84), which was higher than that observed with baseline SVM (AUC = 0.710; difference between areas: 0.099, p \< 0.001), or each single predictor (RO-MO-2 AUC = 0.726, p \< 0.001; RO-MO-3 AUC = 0.717, p \< 0.001; RO-MO-8 AUC = 0.787, p = 0.05; RO-MO-12 AUC = 0.737, p \< 0.001).

It should be noted that the adoption of a DSS incorporating multiple predictors implies that risk evaluation would be represented by a n-level stratification (generated in the event that risk estimate is achieved by all predictors, or by different combinations). In our model, the use of 4 predictors had led to a 5-level stratification, which was barely comparable with the binary classification of the original models or baseline SVM. Thus, instances were re-coded as 1/0 depending on whether they were positive or not to at least three of the RO-MO predictors (DSS predicted class 3 or 4) and ROC curves were re-analyzed. As reported in [Fig. 5](#f0025){ref-type="fig"}, the combined model resulted in an overall improvement of MO risk prediction performance, with a 0.765 AUC, which was higher than that observed with SVM, or each single predictor ([Fig. 3](#f0015){ref-type="fig"}).Fig. 5Comparison between the Receiver Operator Characteristics Curves for ML-based decision support system (DSS) and SVM baseline predictor in the training set.

The improved predictive performance of the ML-based DSS was also confirmed in the test set. As shown in [Fig. 6](#f0030){ref-type="fig"}, in fact, the combined model resulted in an overall improvement of MO risk prediction performance, with an AUC of 0.83, a sensitivity and specificity of 0.69 and 0.87, respectively, and an accuracy of 0.87 when MO was predicted by at least three RO-MO models. Logistic regression analysis further confirmed that the ML-based DSS could effectively distinguish between MO and non-MO with ORs of 5.72 (95%CI: 1.56--20.9) and 21.0 (95%CI: 8.5--52) for patients classified as probably (3 RO-MO predictors positive), or definitely at risk of drug overuse (4 RO-MO predictors positive), respectively.Fig. 6Receiver Operator Characteristics Curve for the combined Decision Support System in the test set.

4. Discussion {#s0030}
=============

The present study was designed to investigate the performance of a novel ML-based methodological approach to derive an AI-based DSS for MO risk assessment in migraine patients.

MO is a challenging problem in migraine, mostly chronic migraine, in which is associated with higher pain intensity scores, symptoms severity and disability [@b0025], [@b0175], as well as the development of MOH [@b0010], [@b0035], [@b0040]. MOH is defined as a headache for ≥15 days/month in a patient with a pre-existing primary headache (usually migraine or tension-type headache), and develops as a consequence of regular overuse (more than three months) of simple analgesics such as non-steroidal anti-inflammatory drugs, acetylsalicylic acid and paracetamol for ≥15 days/month, or analgesic combinations, triptans, ergotamine or opioid for ≥10 days/month [@b0010].

Given the high disability rate of MOH and the treatment challenges it poses [@b0035], prevention is especially important in patients prone to frequent headache and the possibility to predict MO is a compelling challenge in the clinical management of migraine.

Based on previous results [@b0100], [@b0115], [@b0120], [@b0125], [@b0130], we hypothesized that a combined approach of kernel machines and RO of performance would have found a combination of attributes yielding the best classification performance of MO predictors over a test set. The results obtained demonstrated, for the first time to our knowledge, that this approach can be useful in performing an automated prediction for MO, holding the potential for improving model precision through weighting the relative importance of attributes. The clinical soundness of our approach was also supported by the finding that the best scoring models in terms of both f-measure and AUCs were also clinically plausible, as they were all strongly weighted on clinical features (Group 2), which represent some of the major determinants of MO development identified in epidemiological studies [@b0025]. Furthermore, RO-MO-08, the best performing predictor, was substantially weighted on treatment information (use of prophylaxis, different drug classes, or response to triptans), whose role in the development of MO and MOH is also generally accepted [@b0040]. On the other hand, the DBH 19-bp I/D polymorphism, showed irrelevant weights in three of the four models selected for DSS construction, with the exception of RO-MO-03, which may appear in partial disagreement with our previous finding of a significant association between DBH 19-bp I/D polymorphism and MO in inheritance models of genotype-variable association [@b0170]. However, we must acknowledge that while the latter are designed for statistical inference, ML models are designed for prediction and not to prove relationships within the data.

As stated in Section 1, MO is strongly associated to MOH, although it does not necessarily represent its leading cause [@b0010]. Of interest, some of the RO-MO predictors identified in our analysis also showed a discriminatory power for MOH. MOH was present in 9 of the 234 migraine patients included in the test set, 7 of whom (78%) had a positive RO-MO-12 predicted class. Hence, in this patient subset RO-MO-12 was capable of predicting MOH with a sensitivity and specificity of 89% and 71%, respectively, an AUC of 0.80 and a positive likelihood ratio of 3.1 (95% CI: 2.4--3.9) (data not shown). Nonetheless, whether this approach might be useful to identify individuals who will likely develop MOH still needs to be explored.

On the other hand, the analysis of clinical/biochemical variables identified other features possibly associated to MO, which were seldom considered before [@b0180], [@b0185], [@b0190]. This is the case of biochemical features and lifestyle-related attributes, whose relative weight was considerably represented in RO-MO-08 and RO-MO-12, respectively. Previous studies, in fact, suggested that psychiatric co-morbidities (e.g. anxiety disorder or depression) [@b0180], smoking [@b0190], lack of exercise [@b0190] or metabolic syndrome [@b0185] could represent risk factors for the development of MOH. Here, we provide further evidence suggesting that an AI-based approach may exploit significant patterns in data -- connoting causality between individual features and MO -- that can be used to further explore the pathophysiology of MO and MOH in patients with migraine.

The availability of a set of predictive discriminators further allowed the design of a DSS based on a complementary set of four predictors, to investigate whether a combined approach may be of advantage over individual models. The adoption of a model incorporating four predictors allowed to perform a risk evaluation on a five-level stratification and resulted in an overall improvement of MO risk prediction performance over the single predictors, with an AUC of 0.83 and ORs of 5.7 and 21.0 for patients classified as probably (3 RO-MO predictors positive), or definitely at risk of drug overuse (4 RO-MO predictors positive), respectively. This result could be of considerable importance in migraine, where patient education and counseling to avoid MO remains the single most important way to prevent MOH. The possibility to predict those patients at risk for MO, indeed, would help the neurologist to advise people from an early stage and tailor treatment based on individual risk.

The results obtained in the present study are barely comparable with previous studies, as the application of ML to implement medical decision making in migraine has generally addressed the issue of disease classification [@b0065], [@b0070], [@b0075], [@b0080], [@b0085], [@b0090], [@b0095], [@b0100], [@b0195] or treatment outcome prediction [@b0105], [@b0110]. All these studies demonstrated that intelligent systems represent a promising approach for migraine classification, holding potential to revolutionize conventional models of diagnostic deliverance in a contest of personalized medicine. Interestingly, using ML approaches based on magnetic resonance imaging resting-state data [@b0095] or somatosensory evoked potentials [@b0195] it was possible to discriminate migraine patients from healthy subjects with an accuracy of 81% and 88%, respectively. On the other hand, the issue of ML-based risk prediction of MO in migraine has never been addressed before. Even the study by Garcia-Chimeno et al. -- reporting an accuracy \>90% using SVM -- analyzed the possibility to correctly classify between different migraine phenotypes (i.e. episodic vs. chronic migraine with MO) [@b0100]. Conversely, in the present study we specifically addressed the issue of MO risk prediction in patients with various migraine phenotypes, demonstrating that the use of a combined approach of kernel machines and RO of performance outperforms SVM with an accuracy of 87%. This percentage is also higher than that reported by Maizels et al., who demonstrated that the use of a computerized headache assessment tool (CHAT) was able to correctly recognize MO in 82.7% of cases [@b0200].

There are, of course, some limitations to acknowledge. First, the sample size was relatively small, ultimately leading to a small number of recorded events. Second, the model here reported was designed and validated on a dataset derived from a biobank/database project in which all patients are interviewed with a face-to-face semistructured questionnaire detailing in depth demographic and clinical characteristics. Therefore, the population enrolled is highly homogenous and well characterized. Nonetheless, the data here reported demonstrate that the use of ML algorithms and RO models might be of advantage in developing local classifiers capable of predicting MO in migraine, thus supporting the neurologist in the critical phase of migraine clinical and therapeutic decision making. Validation in multicenter prospective studies is needed before making any ML approach into the clinical practice available.

5. Conclusions {#s0035}
==============

In conclusion, a combination of machine learning and random optimization -- taking into consideration clinical and biochemical features, drug exposure and lifestyle -- might represent a valuable approach to MO prediction in migraine. This is particularly appealing in a context of predictive medicine, in which attributes, routinely collected in electronic health records, may be all used to design new tools for clinical and therapeutic decision making. This approach holds the potential for improving model precision through weighting the relative importance of attributes and demonstrates that other variables must be considered in MO risk evaluation, thus strengthening the theory advocated by precision medicine that data should be considered in a more general association, rather than individually.
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